Singapore, Aug. 11 -- France headquartered Sartorius Stedim Biotech, a leading partner to the biopharmaceutical industry, and US-based startup Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered into a partnership.

As part of the collaboration, Sartorius will invest up to $3 million in a minority shareholding in Nanotein Technologies to support the commercialisation and joint development of solutions based on its NanoSpark(R) platform.

Under the exclusive distribution agreement, Sartorius will offer Nanotein's lead products to customers worldwide: the NanoSpark(R) STEM-T Soluble T Cell Activator and NanoSpark(R) GROW-NK Soluble Activator. These reagents are designed to enhance the expansio...